{
    "clinical_study": {
        "@rank": "151378", 
        "arm_group": [
            {
                "arm_group_label": "present 5-aminosalicylic acids+steroids", 
                "arm_group_type": "Active Comparator", 
                "description": "present 5-aminosalicylic takers: maximal 5-aminosalicylic acid by mesalamine/ mesalazine 4 g/day + topical 5-aminosalicylic acid by 1 g/day enema (or suppository if not tolerated) + IV Hydrocortisone 100 mg *3/day"
            }, 
            {
                "arm_group_label": "stop present 5-aminosalicylic acids, take steroids only", 
                "arm_group_type": "Active Comparator", 
                "description": "present 5-aminosalicylic takers: stop 5-aminosalicylic, take only IV Hydrocortisone 100 mg *3/day"
            }, 
            {
                "arm_group_label": "5-aminosalicylic acids+steroids", 
                "arm_group_type": "Active Comparator", 
                "description": "none 5-aminosalicylic takers: maximal 5-aminosalicylic by mesalamine/mesalazine 4 g/day + topical 5-aminosalicylic by 1 g enema/ suppository + IV Hydrocortisone 100 mg *3/day."
            }, 
            {
                "arm_group_label": "none 5-aminosalicylic takers: steroids only", 
                "arm_group_type": "Active Comparator", 
                "description": "none 5-aminosalicylic takers: IV Hydrocortisone 100 mg *3/day"
            }
        ], 
        "brief_summary": {
            "textblock": "The role of steroids in the treatment of ulcerative Colitis (UC) is well established, and\n      recommended by professional societies. However, there are no data investigating whether the\n      addition and/or continuation of 5-aminosalicylic agents as combination therapy with systemic\n      corticosteroids is superior to corticosteroids alone in patients with moderate-severe active\n      UC. Thus, in practical terms, the decision regarding 5-aminosalicylic (to add or continue),\n      on top of steroids treatment, is taken on an arbitrary basis. The aim of this study is to\n      compare the efficacy of steroids alone Vs combination of steroids + 5-aminosalicylic in the\n      treatment of moderate-severe UC exacerbation."
        }, 
        "brief_title": "Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Ulcerative Colitis.", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ulcerative Colitis known for at least 3 months prior to admission\n\n          -  current hospitalization with severe Ulcerative Colitis exacerbation\n\n          -  age >18\n\n          -  hasn't been on oral systemic steroids 7 days prior to admission\n\n          -  if taking thiopurines, the dose must be stable for 2 months prior to admission\n\n        Exclusion Criteria:\n\n          -  pregnant women\n\n          -  allergy/unable to take study medications\n\n          -  active infection\n\n          -  severe renal/liver/cardiorespiratory condition\n\n          -  toxic megacolon or signs of imminent colectomy\n\n          -  treatment with an anti-tumor necrosis factor  in 3 months prior to admission\n\n          -  prior treatment with cyclosporin or tacrolimus\n\n          -  alcohol dependancy\n\n          -  unwilling/ unable to give an informed consent\n\n          -  participation in clinical trials in the last 2 months prior to admission"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941589", 
            "org_study_id": "SHEBA-13-0401-OH-CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "present 5-aminosalicylic acids+steroids", 
                    "5-aminosalicylic acids+steroids"
                ], 
                "description": "combination 5-aminosalicylic + hydrocortisone / prednisone", 
                "intervention_name": "combination 5-aminosalicylic + hydrocortisone / prednisone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "rafassal", 
                    "pentasa", 
                    "asacol", 
                    "hydrocortisone", 
                    "solu-cortef", 
                    "prednisone", 
                    "prenitone"
                ]
            }, 
            {
                "arm_group_label": [
                    "stop present 5-aminosalicylic acids, take steroids only", 
                    "none 5-aminosalicylic takers: steroids only"
                ], 
                "description": "IV hydrocortisone / PO prednisone", 
                "intervention_name": "IV hydrocortisone / PO prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aminosalicylic Acid", 
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Prednisone", 
                "Mesalamine", 
                "Hydrocortisone-17-butyrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "tel-Hashomer, Ramat-Gan", 
                        "country": "Israel", 
                        "zip": "52621"
                    }, 
                    "name": "Sheba Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ofir Har-Noy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ofirharnoy@gmail.com", 
                    "last_name": "Ofir Har-Noy, MD", 
                    "phone": "+972-3-530-2679"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel-Hashomer, Ramat-Gan", 
                        "country": "Israel", 
                        "zip": "52621"
                    }, 
                    "name": "Sheba Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ofir Har-Noy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "4", 
        "official_title": "Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.", 
        "other_outcome": {
            "measure": "duration of hospitalization", 
            "safety_issue": "No", 
            "time_frame": "3-90"
        }, 
        "overall_contact": {
            "email": "ofirharnoy@gmail.com", 
            "last_name": "Ofir Har-Noy, MD", 
            "phone": "+972-3-530-2679"
        }, 
        "overall_contact_backup": {
            "email": "sben-horin@013net.net", 
            "last_name": "Shomron Ben-Horin, MD", 
            "phone": "+972-3-530-2679"
        }, 
        "overall_official": {
            "affiliation": "Sheba Medical Center, Tel-Hashomer, ISRAEL 52621", 
            "last_name": "Ofir Har-Noy, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "percentage of patients who respond to the treatment", 
            "safety_issue": "Yes", 
            "time_frame": "day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941589"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheba Medical Center", 
            "investigator_full_name": "Dr. Ofir Harnoy MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "the percentage of patients in need of a rescue medication", 
                "safety_issue": "Yes", 
                "time_frame": "day 5, 7"
            }, 
            {
                "measure": "colectomy rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 month, 3 months post randomization"
            }
        ], 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}